Saskia Middeldorp

Saskia Middeldorp (1966) is professor of Medicine and heads the Department of Internal Medicine of the Radboud University Medical Center in Nijmegen, The Netherlands. She was full professor of Medicine at Amsterdam University Medical Centers (2010-2020) where she led the thrombosis and haemostasis research lines. Her research focuses on hereditary and acquired thrombophilia (i.e. risk factors for thrombosis), with a strong focus on generating evidence on optimal use of anticoagulants in pregnant women. She is principal investigator of practice-changing academic trials of anticoagulant therapy in pregnant women, such as the ALIFE (NEJM 2010), ALIFE2 (Lancet 2023) and Highlow (Lancet 2022) randomized controlled trials. She is also involved in the development of new anticoagulant drugs and its antidotes. Currently, she is investigating the role of innate immunity in antiphospholipid syndrome.